A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

Laboratory markers of immune depression included early and persistent neutropenia, as well as early and persistent lymphopenia. The Fisher exact and Wilcoxon rank-sum tests were used in statistical ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells ...

Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with ...

DOC WILLIE ONG - The celebrity cardiologist revealed going critical because of "neutropenic sepsis" through a video.

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.